News from Trillium Therapeutics Inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

06 Sep, 2012, 07:00 ET Trillium's anti-CD47 oncology program highlighted in prestigious journal

TORONTO, Sept. 6, 2012 /PRNewswire/ - Trillium Therapeutics Inc. (TTI), a biopharmaceutical company developing innovative and proprietary...


04 Apr, 2012, 13:00 ET Trillium provides update on anti-CD47 cancer program

TORONTO, April 4, 2012 /PRNewswire/ - Trillium Therapeutics Inc., a privately-held biopharmaceutical company developing proprietary and...


28 Mar, 2012, 07:00 ET First Patient Treated in Trillium's Interstitial Cystitis/Bladder Pain Syndrome Clinical Trial

TORONTO, March 28, 2012 /PRNewswire/ - Trillium Therapeutics Inc., a privately-held biopharmaceutical company developing proprietary and...


15 Dec, 2011, 07:00 ET Trillium to Commence Clinical Testing of TTI-1612 in Patients with Interstitial Cystitis/Bladder Pain Syndrome

TORONTO, Dec. 15, 2011 /PRNewswire/ -Trillium Therapeutics Inc., a privately-held biopharmaceutical company developing proprietary and innovative...


12 May, 2011, 07:00 ET Trillium raises funds to advance urology program into clinical trials

A new and innovative approach to the treatment of interstitial cystitis TORONTO, May 12 /PRNewswire/ - Trillium Therapeutics Inc., a...


02 Dec, 2010, 11:00 ET Trillium's Cancer Stem Cell Program to be Highlighted at ASH

TORONTO, Dec. 2 /PRNewswire/ - Trillium Therapeutics Inc. (TTI), a biopharmaceutical company developing innovative immune-based biologics, today...


11 Mar, 2010, 07:00 ET Trillium expands immunology pipeline and enters stem cell field through in-licensing of two new programs

TORONTO, March 11 /PRNewswire/ - Trillium Therapeutics Inc. (TTI), a biopharmaceutical company developing innovative immune-based biologics, today...


28 Jan, 2010, 07:00 ET Trillium adds industry veteran Dr. Mike Gresser to its Board of Directors

TORONTO, Jan. 28 /PRNewswire/ - Trillium Therapeutics Inc. (TTI), a biopharmaceutical company developing innovative immune-based biologics, today...


12 Jan, 2010, 10:00 ET Trillium and Biogen Idec enter into global license agreement

TORONTO, Jan. 12 /PRNewswire/ - Trillium Therapeutics Inc. (TTI), a biopharmaceutical company developing innovative immune-based biologics, today...


05 Nov, 2008, 07:30 ET Trillium Strengthens its Board of Directors

TORONTO, Nov. 5 /PRNewswire/ - Trillium Therapeutics Inc., a privately held biopharmaceutical company, announced today that industry veterans...


19 Dec, 2006, 00:00 ET Trillium's TTI-1612 product receives orphan drug designation in Europe and the United States

TORONTO, Dec. 19 /PRNewswire/ - Trillium Therapeutics Inc. (Trillium) today announced that its gastrointestinal product, TTI-1612, has been...


06 Oct, 2005, 01:00 ET Trillium acquires Arthron Ltd.

TORONTO, Oct. 6 /PRNewswire/ - Trillium Therapeutics Inc. (TTI), a Canadian biopharmaceutical company, today announced that it has acquired all...


23 Feb, 2004, 00:00 ET Trillium Therapeutics Welcomes Dr. Michael Moore to Board of Directors

TORONTO, Feb. 23 /PRNewswire/ - Trillium Therapeutics Inc. (TTI) announced today that Dr. Michael Moore, Chief Executive Officer of PIramed, has...


05 Feb, 2004, 00:00 ET Trillium Therapeutics Raises an Additional $6.0 Million to Close Series A Round at $13.5 million

TORONTO, Feb. 5 /PRNewswire/ - Trillium Therapeutics Inc. (TTI) announced today that the Company has raised an additional $6 million, bringing the...